Cabecera 2019 CBMSO CSIC UAM

Sunday, 25th August 2019

Regulation of gene expression in Leishmania

 FotoGrupo 26Jul17

 


José María Requena Rolanía 

ESciStaff

EPublications

Research summary:

 

The research activity of our group has been focused on molecular aspects of the protist Leishmania and the immunopathology that the infection of this parasite causes. On the one hand, we have continued studying molecular processes associated with the peculiar mechanisms of gene expression in an organism in which transcriptional regulation is almost absent. On the other hand, we have conducted activities aimed to develop strategies to control leishmaniasis, a disease that continues affecting millions of people worldwide.

 

By using massive sequencing techniques, we are studying the transcriptomes of several Leishmania species (and improving the genomic annotations) with the goal of identifying both regulatory cis-elements, often found in the 3’ untranslated regions (UTRs) of mRNAs, and RNA-binding proteins (RBPs), as key players in the regulation of gene expression. These tasks are being done in close collaboration with Dr. Begoña Aguado (also at CBMSO). In order to give visibility to the results of our studies and to facilitate the use of the generated data, we have designed the Web page Leish-ESP (http://leish-esp.cbm.uam.es/).

 

Within the research line on immunopathological aspects of leishmaniasis, headed by Dr. Manuel Soto, we are studying the interactions between Leishmania and the mammalian immune system, characterizing parasite factors able to interfere with the induction of protective immune responses. Additionally, new strategies for the development of specific treatments, diagnostic systems as well as vaccines are being explored from the analysis of samples derived from human and canine patients, together with animal models of experimental leishmaniasis. Also, we are participating in a project granted by the European Commission’s FP7 Cooperation Work Program for Health; this project entitled Clinical Studies on a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin; EU contract 603181) is aimed to develop a vaccine against human visceral leishmaniasis (http://www.mulevaclin.eu). Finally, as members of the Tropical Diseases network (ISCIII; http://www.ricet.es/es/), our group is engaged in collaborative activities with clinical teams.

fig01.300px

 Regulation of gene expression in Leishmania occurs exclusively at the post-transcriptional level

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

Publications:

  • Requena, J.M., Chicharro, C., Garcia, L., Parrado, R., Puerta, C.J. and Cañavate, C. (2012). Sequence analysis of the 3'-untranslated region of HSP70 (type I) genes in the genus Leishmania: its usefulness as a molecular marker for species identification. Parasites & Vectors 5: 87. PMID: 22541251
  • Rastrojo, A., Carrasco-Ramiro, F., Martín, D., Crespillo, A., Reguera, R.M., Aguado, B. and Requena, J.M. (2013). The transcriptome of Leishmania major in the axenic promastigote stage: transcript annotation and relative expression levels by RNA-seq. BMC Genomics 14(1):223. PMID: 23557257
  • Fraga, J., Montalvo, A.M., Van der Auwera, G., Maes, I., Dujardin, J.C., and Requena, J.M. (2013). Evolution and species discrimination according to the Leishmania heat-shock protein 20 gene. Infect Genet Evol 18: 229-237. PMID: 23722022
  • Ramirez, C.A., Requena, J.M., and Puerta, C.J. (2013). Alpha tubulin genes from Leishmania braziliensis: genomic organization, gene structure and insights on their expression. BMC Genomics 14, 454. PMID: 23829570
  • Ramirez, C.A., Dea-Ayuela, M.A., Gutierrez-Blazquez, M.D., Bolas-Fernandez, F., Requena, J.M., and Puerta, C.J. (2013). Identification of proteins interacting with HSP70 mRNAs in Leishmania braziliensis. J. Proteomics 94: 124-137. PMID: 24060997
  • Montalvo, A.M., Fraga, J., Rodriguez, O., Blanco, O., Llanos-Cuentas, A., Garcia, A.L., Valencia, B.M., Muskus, C., Van der Auwera, G., and Requena, J.M. (2014). Detección de Leishmania spp. en base al gen que codifica la proteína HSP20. Rev Peru Med Exp Salud Publica 31: 635-643. PMID: 25597712
  • Nocua, P.A., Ramirez, C.A., Barreto, G.E., Gonzalez, J., Requena, J.M., and Puerta, C.J. (2014). Leishmania braziliensis replication protein A subunit 1: molecular modelling, protein expression and analysis of its affinity for both DNA and RNA. Parasites & Vectors 7: 573. PMID: 25498946
  • Requena, J.M., Montalvo, A.M., and Fraga, J. (2015). Molecular Chaperones of Leishmania: Central Players in Many Stress-Related and -Unrelated Physiological Processes. Biomed Res Int 2015: 301326. PMID: 26167482
  • Alonso, G., Rastrojo, A., Lopez-Perez, S., Requena, J.M., and Aguado, B. (2016). Resequencing and assembly of seven complex loci to improve the Leishmania major (Friedlin strain) reference genome. Parasites & Vectors 9: 74. PMID: 26857920
  • Fernandez-Orgiler, A., Martinez-Jimenez, M.I., Alonso, A., Alcolea, P.J., Requena, J.M., Thomas, M.C., Blanco, L., and Larraga, V. (2016). A putative Leishmania DNA polymerase theta protects the parasite against oxidative damage. Nucleic Acids Res 44: 4855-4870. PMID: 27131366
  • Lombraña, R., Alvarez, A., Fernandez-Justel, J.M., Almeida, R., Poza-Carrion, C., Gomes, F., Calzada, A., Requena, J.M., and Gomez, M. (2016). Transcriptionally Driven DNA Replication Program of the Human Parasite Leishmania major. Cell Rep 16: 1774-1786. PMID: 27477279
  • Requena, J.M., Rastrojo, A., Garde, E., Lopez, M.C., Thomas, M.C., and Aguado, B. (2017). Genomic cartography and proposal of nomenclature for the repeated, interspersed elements of the Leishmania major SIDER2 family and identification of SIDER2-containing transcripts. Mol Biochem Parasitol 212, 9-15. PMID: 28034676
  • Requena, J.M., Rastrojo, A., Garde, E., Lopez, M.C., Thomas, M.C., and Aguado, B. (2017). Dataset for distribution of SIDER2 elements in the Leishmania major genome and transcriptome. Data Brief 11, 39-43. PMID: 28127581
  • Solana, J.C., Ramirez, L., Corvo, L., de Oliveira, C.I., Barral-Netto, M., Requena, J.M., Iborra, S., and Soto, M. (2017). Vaccination with a Leishmania infantum HSP70-II null mutant confers long-term protective immunity against Leishmania major infection in two mice models. PLoS neglected tropical diseases 11, e0005644. PMID: 28558043
  • Nocua, P.A., Ramirez, C.A., Requena*, J.M., and Puerta*, C.J. (2017). Leishmania braziliensis SCD6 and RBP42 proteins, two factors with RNA binding capacity. Parasites & vectors 10, 610. *C.A. PMID: 29258569
  • Gonzalez-de la Fuente, S., Peiro-Pastor, R., Rastrojo, A., Moreno, J., Carrasco-Ramiro, F., Requena*, J.M., and Aguado*, B. (2017). Resequencing of the Leishmania infantum (strain JPCM5) genome and de novo assembly into 36 contigs. Sci Rep 7, 18050. *C.A. PMID: 29273719
  • Diaz, J.R., Ramirez, C.A., Nocua, P.A., Guzman, F., Requena, J.M., and Puerta, C.J. (2018). Dipeptidyl peptidase 3, a novel protease from Leishmania braziliensis. PLoS One 13, e0190618. PMID: 29304092

 

Books:

Stress Response in Microbiology. Caister Academic Press. Editor: Jose M. Requena. June 2012. ISBN: 978-1-908230-04-1. NLM ID: 101587947


 

Patents:

Jose M. Requena Rolanía, J.M., Cristina Folgueira Fernández, C., Carrión Herrero, J. y Manuel Fresno Escudero, M. (2010) Use of strains of Leishmania ΔHSP70-II as a vaccine. Universidad Autónoma de Madrid. PCT/ES2010/070073.

NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand

COOKIES POLICY

What are cookies?

A cookie is a file that is downloaded to your computer when you access certain web pages. Cookies allow a web page, among other things, to store and retrieve information about the browsing habits of a user or their equipment and, depending on the information they contain and the way they use their equipment, they can be used to recognize the user.

Types of cookies

Classification of cookies is made according to a series of categories. However, it is necessary to take into account that the same cookie can be included in more than one category.

  1. Cookies according to the entity that manages them

    Depending on the entity that manages the computer or domain from which the cookies are sent and treat the data obtained, we can distinguish:

    • Own cookies: those that are sent to the user's terminal equipment from a computer or domain managed by the editor itself and from which the service requested by the user is provided.
    • Third party cookies: those that are sent to the user's terminal equipment from a computer or domain that is not managed by the publisher, but by another entity that processes the data obtained through the cookies. When cookies are installed from a computer or domain managed by the publisher itself, but the information collected through them is managed by a third party, they cannot be considered as own cookies.

  2. Cookies according to the period of time they remain activated

    Depending on the length of time that they remain activated in the terminal equipment, we can distinguish:

    • Session cookies: type of cookies designed to collect and store data while the user accesses a web page. They are usually used to store information that only is kept to provide the service requested by the user on a single occasion (e.g. a list of products purchased).
    • Persistent cookies: type of cookies in which the data is still stored in the terminal and can be accessed and processed during a period defined by the person responsible for the cookie, which can range from a few minutes to several years.

  3. Cookies according to their purpose

    Depending on the purpose for which the data obtained through cookies are processed, we can distinguish between:

    • Technical cookies: those that allow the user to navigate through a web page, platform or application and the use of different options or services that exist in it, such as controlling traffic and data communication, identifying the session, access to restricted access parts, remember the elements that make up an order, perform the purchase process of an order, make a registration or participation in an event, use security elements during navigation, store content for the broadcast videos or sound or share content through social networks.
    • Personalization cookies: those that allow the user to access the service with some predefined general characteristics based on a series of criteria in the user's terminal, such as the language, the type of browser through which the user accesses the service, the regional configuration from where you access the service, etc.
    • Analytical cookies: those that allow the person responsible for them to monitor and analyse the behaviour of the users of the websites to which they are linked. The information collected through this type of cookies is used in the measurement of the activity of the websites, applications or platforms, and for the elaboration of navigation profiles of the users of said sites, applications and platforms, in order to introduce improvements in the analysis of the data of use made by the users of the service.

Cookies used on our website

The CBMSO website uses Google Analytics. Google Analytics is a simple and easy to use tool that helps website owners to measure how users interact with the content of the site. You can consult more information about the cookies used by Google Analitycs in this link.

Acceptance of the Cookies Policy

The CBMSO assumes that you accept the use of cookies if you continue browsing, considering that it is a conscious and positive action from which the user's consent is inferred. In this regard, you are previously informed that such behaviour will be interpreted that you accept the installation and use of cookies.

Knowing this information, it is possible to carry out the following actions:

How to modify the configuration of cookies

Using your browser you can restrict, block or delete cookies from any web page. In each browser the process is different, here we show you links on this particular of the most used browsers: